Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment.
The kynurenine pathway from tryptophan generates compounds which can act on glutamate receptors in peripheral tissues or modulate free radical activity. We have measured the concentrations of several of these compounds in the plasma of patients with rheumatoid arthritis (RA) and osteoporosis (OP) before treatment with drugs and then at monthly intervals for 6 months during treatment. Kynurenine analysis was performed by HPLC. Compared with healthy controls, RA patients showed significantly decreased baseline levels of tryptophan, 3-hydroxykynurenine and 3-hydroxyanthranilic acid and increased levels of kynurenine and xanthurenic acid, while kynurenic acid concentrations were normal. Different results were recorded from patients with OP with only a significant reduction in tryptophan and 3-hydroxyanthranilic acid when compared with healthy controls. During 6 months of treating the RA patients with prednisolone or methotrexate, and the OP patients with raloxifene or etidronate and calcium there were significant therapeutic responses and a significant trend towards a reduction in levels of neopterin in RA patients receiving methotrexate but no changes in the profiles of tryptophan metabolites. The results are consistent with the induction of indoleamine-2,3-dioxygenase (IDO) in both RA and OP but with far greater activation of the pathway in the much more inflammatory condition, i.e. RA. It is concluded that there are changes in the kynurenine pathway, which may modify the activation of tissue glutamate receptors, in RA and OP, but that these are not affected by the drug treatments studied.
Forrest
Caroline M
CM
Institute of Biomedical & Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
Kennedy
Alan
A
Stone
Trevor W
TW
Stoy
Nicholas
N
Darlington
L Gail
LG
D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D016022:Case-Control Studies; D012968:Etidronic Acid / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007737:Kynurenine / Q000097:blood*; D008727:Methotrexate / Q000627:therapeutic use; D019798:Neopterin / Q000097:blood*; D010024:Osteoporosis / Q000097:blood* / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D017470:Receptors, Glutamate / Q000378:metabolism; D014364:Tryptophan / Q000097:blood
D017470:Receptors, Glutamate; D007737:Kynurenine; D020849:Raloxifene Hydrochloride; D019798:Neopterin; D014364:Tryptophan; D011239:Prednisolone; D012968:Etidronic Acid; D008727:Methotrexate